Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen | Zendy

Paul M. Ridker | Zendy; Campbell P. Howard | Zendy; Verena Walter | Zendy; Giulia Renda | Zendy; Peter Libby | Zendy; Johannes Hensen | Zendy; Tom Thurén | Zendy

Open Access

Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen

Author(s) -

Paul M. Ridker,

Campbell P. Howard,

Verena Walter,

Giulia Renda,

Peter Libby,

Johannes Hensen,

Tom Thurén

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.122556

Subject(s) - canakinumab , medicine , placebo , fibrinogen , triglyceride , c reactive protein , endocrinology , cholesterol , gastroenterology , inflammation , pathology , anakinra , disease , alternative medicine

To test formally the inflammatory hypothesis of atherothrombosis, an agent is needed that reduces inflammatory biomarkers such as C-reactive protein, interleukin-6, and fibrinogen but that does not have major effects on lipid pathways associated with disease progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research